Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials

Gao,Shan; Fan,Ling; Yu,Zhigang; Xie,Xingxing

doi:10.3892/br.2024.1779

Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials

Authors:
- Shan Gao
- Ling Fan
- Zhigang Yu
- Xingxing Xie
View Affiliations

Affiliations: Department of Pharmacy, Chengdu Second People's Hospital, Chengdu, Sichuan 618000, P.R. China, Department of Good Clinical Practice, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China, Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
Published online on: April 11, 2024 https://doi.org/10.3892/br.2024.1779
Article Number: 91
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lurasidone is an atypical anti‑psychotic approved by the US Food and Drug Administration. It is mainly used to treat schizophrenia in adults through its antagonistic action on dopamine and 5‑hydroxytryptamine receptors. The present study systematically assessed the efficacy and safety of lurasidone in the treatment of schizophrenia. Clinical, double‑blind, parallel, randomized controlled trials (RCTs) of lurasidone in the treatment of schizophrenia were retrieved from PubMed\Medline, EBSCO, Embase, Cochrane Library, OVID, Web of Science and related clinical trial registration websites up to May 2023. A total of two investigators independently screened the included references and evaluated their quality. RevMan 5.3 software was used for meta‑analysis of each measure outcome. The present systematic review was registered in PROSPERO (ID=CRD42018108178). A total of eight RCTs were included in the present study, including a total of 2,456 patients with schizophrenia. All eight references were randomized, double‑blind and parallel control trials. All eight references were evaluated as high quality. The meta‑analysis results demonstrated that there were no significant change in total Positive and Negative Syndrome Scale (PANSS) score, Clinical Global Impression of Severity (CGI‑S) score and Montgomery‑Asberg Depression Rating Scale (MADRS) between the 40 mg lurasidone group and the placebo group (P>0.05). However, as the dosage increased, the 80, 120 and 160 mg lurasidone groups had significant changes in total PANSS score, CGI‑S score and MADRS Compared with placebo (P<0.05), although changes in MADRS in the 120 mg lurasidone group were not statistically significant (P>0.05). In terms of safety, the changes in the incidence of agitation in the 40 mg lurasidone group (P<0.05), vomiting in the 80 mg group (P<0.05) and akathisia in the 160 mg group (P<0.05) were statistically significant and there were also statistically significant changes in the incidence of akathisia, nausea, somnolence and extrapyramidal disorder among the 40, 80 and 120 mg lurasidone groups (P<0.05); No statistically significant changes in the in the incidence of other adverse reactions (P>0.05). In conclusion, existing evidence suggests that the initial dose of lurasidone for schizophrenia can be adjusted to 80 mg. As the condition aggravates, the dose can be incrementally increased to 160 mg. A dose of 160 mg lurasidone is recommended as the most efficacious and safe dose for acute schizophrenia and the risk of occurrence of akathisia, nausea, somnolence and extrapyramidal disorder is still high when lurasidone is administered at a dose of 80‑120 mg. The dose should be promptly adjusted or the drug should be withdrawn if the aforementioned adverse reactions worsen. Multi‑center, high‑quality and long‑term clinical RCTs influenced by the included references are still necessary to support the aforementioned conclusions.

View Figures

View References

1	Henson P, D'Mello R, Vaidyam A, Keshavan M and Torous J: Anomaly detection to predict relapse risk in schizophrenia. Transl Psychiatry. 11(28)2021.PubMed/NCBI View Article : Google Scholar
2	Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, et al: International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 27:1064–1076. 2017.PubMed/NCBI View Article : Google Scholar
3	Sun ZW, Shi TT and Fu PX: Characteristics of schizophrenia patients' homicide behaviors and their correlations with criminal capacity. Fa Yi Xue Za Zhi. 33:32–35. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
4	Maggioni E, Crespo-Facorro B, Nenadic I, Benedetti F, Gaser C, Sauer H, Roiz-Santiañez R, Poletti S, Marinelli V, Bellani M, et al: Common and distinct structural features of schizophrenia and bipolar disorder: The European network on psychosis, affective disorders and cognitive trajectory (ENPACT) study. PLoS One. 12(e0188000)2017.PubMed/NCBI View Article : Google Scholar
5	Wimberley T, MacCabe JH, Laursen TM, Sørensen HJ, Astrup A, Horsdal HT, Gasse C and Støvring H: Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry. 174:990–998. 2017.PubMed/NCBI View Article : Google Scholar
6	Cai C and Yu L: Quality of life in patients with schizophrenia in China: Relationships among demographic characteristics, psychosocial variables, and symptom severity. J Psychosoc Nurs Ment Health Serv. 55:48–54. 2017.PubMed/NCBI View Article : Google Scholar
7	Li W, Zhou FC, Zhang L, Ng CH, Ungvari GS, Li J and Xiang YT: Comparison of cognitive dysfunction between schizophrenia and bipolar disorder patients: A meta-analysis of comparative studies. J Affect Disord. 274:652–661. 2020.PubMed/NCBI View Article : Google Scholar
8	Wang LJ, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC and Chen CK: Differences in clinical features of methamphetamine users with persistent psychosis and patients with schizophrenia. Psychopathology. 49:108–115. 2016.PubMed/NCBI View Article : Google Scholar
9	Tan EJ, Neill E and Rossell SL: Assessing the relationship between semantic processing and thought disorder symptoms in schizophrenia. J Int Neuropsychol Soc. 21:629–638. 2015.PubMed/NCBI View Article : Google Scholar
10	Kurtz M, Mohring P, Förster K, Bauer M and Kanske P: Deficits in explicit emotion regulation in bipolar disorder: A systematic review. Int J Bipolar Disord. 9(15)2021.PubMed/NCBI View Article : Google Scholar
11	Reutfors J, Cesta CE, Cohen JM, Bateman BT, Brauer R, Einarsdóttir K, Engeland A, Furu K, Gissler M, Havard A, et al: Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophr Res. 220:106–115. 2020.PubMed/NCBI View Article : Google Scholar
12	Bruijnzeel D, Yazdanpanah M, Suryadevara U and Tandon R: Lurasidone in the treatment of schizophrenia: A critical evaluation. Expert Opin Pharmacother. 16:1559–1565. 2015.PubMed/NCBI View Article : Google Scholar
13	Citrome L: Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Prefer Adherence. 10:1529–1537. 2016.PubMed/NCBI View Article : Google Scholar
14	Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T and Taiji M: The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and morris water maze tests in rats: Mechanistic implications for the benefcial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res. 220:83–90. 2011.PubMed/NCBI View Article : Google Scholar
15	Srisurapanont M, Suttajit S, Likhitsathian S, Maneeton B and Maneeton N: A network meta-analysis of the dose-response effects of lurasidone on acute schizophrenia. Sci Rep. 11(5571)2021.PubMed/NCBI View Article : Google Scholar
16	Kishi T, Nosaka T, Sakuma K, Okuya M and Iwata N: Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacol Rep. 40:314–322. 2020.PubMed/NCBI View Article : Google Scholar
17	Braga VL, Rocha LPDS, Bernardo DD, Cruz CO and Riera R: What do Cochrane systematic reviews say about probiotics as preventive interventions? Sao Paulo Med J. 135:578–586. 2017.PubMed/NCBI View Article : Google Scholar
18	Moher D, Liberati A, Tetzlaff J and Altman DG: PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6(e1000097)2009.PubMed/NCBI View Article : Google Scholar
19	Page MJ and Moher D: Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and extensions: A scoping review. Syst Rev. 6(263)2017.PubMed/NCBI View Article : Google Scholar
20	Knobloch K, Yoon U and Vogt PM: Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 39:91–92. 2011.PubMed/NCBI View Article : Google Scholar
21	Panic N, Leoncini E, de Belvis G, Ricciardi W and Boccia S: Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 8(e83138)2013.PubMed/NCBI View Article : Google Scholar
22	Durak S, Ercan ES, Ardic UA, Yuce D, Ercan E and Ipci M: Effect of methylphenidate on neurocognitive test battery: An evaluation according to the diagnostic and statistical manual of mental disorders, fourth edition, subtypes. J Clin Psychopharmacol. 34:467–474. 2014.PubMed/NCBI View Article : Google Scholar
23	Shabsigh R and Rowland D: The diagnostic and statistical manual of mental disorders, fourth edition, text revision as an appropriate diagnostic for premature ejaculation. J Sex Med. 4:1468–1478. 2007.PubMed/NCBI View Article : Google Scholar
24	Faiad Y, Khoury B, Daouk S, Maj M, Keeley J, Gureje O and Reed G: Frequency of use of the international classification of diseases ICD-10 diagnostic categories for mental and behavioural disorders across world regions. Epidemiol Psychiatr Sci. 9:568–576. 2018.PubMed/NCBI View Article : Google Scholar
25	Janca A, Ustün TB, Early TS and Sartorius N: The ICD-10 symptom checklist: A companion to the ICD-10 classification of mental and behavioural disorders. Soc Psychiatry Psychiatr Epidemiol. 28:239–242. 1993.PubMed/NCBI View Article : Google Scholar
26	International Advisory Group for the Revision of ICD-10 Mental and Behavioural Disorders. A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders. World Psychiatry. 10:86–92. 2011.PubMed/NCBI View Article : Google Scholar
27	Khan A, Lewis C and Lindenmayer JP: Use of non-parametric item response theory to develop a shortened version of the positive and negative syndrome scale (PANSS). BMC Psychiatry. 11(178)2011.PubMed/NCBI View Article : Google Scholar
28	Pinna F, Deriu L, Diana E, Perra V, Randaccio RP, Sanna L, Tusconi M and Carpiniello B: Cagliari Recovery Study Group. Clinical global impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders. Ann Gen Psychiatry. 14(6)2015.PubMed/NCBI View Article : Google Scholar
29	Health Quality Ontario. Psychotherapy for Major depressive disorder and generalized anxiety disorder: A health technology assessment. Ont Health Technol Assess Ser. 17:1–167. 2017.PubMed/NCBI
30	Higgins JPT and Green S (eds): Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from. http://handbook.cochrane.org.
31	Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A and Potkin SG: Efficacy and safety of lurasidone 80 and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 145:101–109. 2013.PubMed/NCBI View Article : Google Scholar
32	Ogasa M, Kimura T, Nakamura M and Guarino J: Lurasidone in the treatment of schizophrenia: A 6-week, placebo-controlled study. Psychopharmacology (Berl). 225:519–530. 2013.PubMed/NCBI View Article : Google Scholar
33	Goldman R, Loebel A, Cucchiaro J, Deng L and Findling RL: Efficacy and safety of lurasidone in adolescents with schizophrenia: A 6-week, randomized placebo-controlled study. J Child Adolesc Psychopharmacol. 27:516–525. 2017.PubMed/NCBI View Article : Google Scholar
34	Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A and Loebel A: Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 168:957–967. 2011.PubMed/NCBI View Article : Google Scholar
35	Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J and Loebel A: Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J Psychiatr Res. 47:670–677. 2013.PubMed/NCBI View Article : Google Scholar
36	Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J and Loebel A: Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial. J Clin Psychiatry. 70:829–836. 2009.PubMed/NCBI View Article : Google Scholar
37	Potkin SG, Kimura T and Guarino J: A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 5:322–331. 2015.PubMed/NCBI View Article : Google Scholar
38	Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L and Kane JM: Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J Clin Psychiatry. 77:1672–1680. 2016.PubMed/NCBI View Article : Google Scholar
39	Sanford M: Lurasidone: In the treatment of schizophrenia. CNS Drugs. 27:67–80. 2013.PubMed/NCBI View Article : Google Scholar
40	Owen RT: Lurasidone: A new treatment option for schizophrenia. Drugs Today (Barc). 47:807–816. 2011.PubMed/NCBI View Article : Google Scholar
41	Latuda. (lurasidone HCl) Tablets US Prescribing Information, 2012. http://www.latuda.com/LatudaPrescribingInformation.pdf.
42	Kane JM: Lurasidone: A clinical overview. J Clin Psychiatry. 72 (Suppl 1):S24–S28. 2011.PubMed/NCBI View Article : Google Scholar
43	Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, et al: Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 334:171–181. 2010.PubMed/NCBI View Article : Google Scholar
44	Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ and Warburton KD: ‘Meta-guidelines’ for the management of patients with schizophrenia. CNS Spectr. 18:150–162. 2013.PubMed/NCBI View Article : Google Scholar
45	Stahl SM: Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. 5th edition. Cambridge, UK: Cambridge University Press, 2021.
46	De Hert M, Yu W, Detraux J, Sweers K, van Winkel R and Correll CU: Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-analysis. CNS Drugs. 26:733–759. 2012.PubMed/NCBI View Article : Google Scholar
47	Fukuyama K, Motomura E, Shiroyama T and Okada M: Impact of 5-HT7 receptor inverse agonism of lurasidone on monoaminergic tripartite synaptic transmission and pathophysiology of lower risk of weight gain. Biomed Pharmacother. 148(112750)2022.PubMed/NCBI View Article : Google Scholar
48	Tarzian M, Soudan M, Alhajji M, Ndrio M and Fakoya AO: Lurasidone for treating schizophrenia and bipolar depression: A review of its efficacy. Cureus. 15(e38071)2023.PubMed/NCBI View Article : Google Scholar
49	Higuchi T, Ishigooka J, Iyo M, Yeh CB, Ebenezer EG, Liang KY, Lee JS, Lee SY, Lin SK, Yoon BH, et al: Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia Pac Psychiatry. 11(e12352)2019.PubMed/NCBI View Article : Google Scholar
50	Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A and Loebel A: Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: A 6-month, open-label, extension study. J Clin Psychiatry. 74:507–515. 2013.PubMed/NCBI View Article : Google Scholar
51	Miura I, Horikoshi S, Ichinose M, Suzuki Y and Watanabe K: Lurasidone for the treatment of schizophrenia: Design, development, and place in therapy. Drug Des Devel Ther. 17:3023–3031. 2023.PubMed/NCBI View Article : Google Scholar
52	Harvey PD, Ogasa M, Cucchiaro J, Loebel A and Keefe RS: Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone. Schizophr Res. 127:188–194. 2011.PubMed/NCBI View Article : Google Scholar
53	Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, Ungvari GS, Li XB, Ning YP and Xiang YT: Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. J Psychiatr Res. 103:244–251. 2018.PubMed/NCBI View Article : Google Scholar